For example, the GIS threshold used to identify ovarian tumors which are HRD positive is similar to that employed to determine the HRD status of triple-negative breast cancers but not for estrogen receptor-positive breast cancers [159]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.